From Published Clinical Evidence to Market Authorization

key principles and best practices

Expanding the intended use of a medical device in the United States is often assumed to require new clinical investigations. However, FDA regulations and guidance recognize that published clinical literature when rigorously identified, assessed, and synthesized can serve as valid scientific evidence to support safety and effectiveness. This article outlines key principles and best practices for using published clinical literature to support regulatory decision-making, including expanded indications/labeling, with a focus on how a systematic, regulator-ready literature review strategy drives success.

Principle 1: Start with a Clearly Defined Regulatory Question

FDA evaluates evidence in a question-driven framework, not a descriptive one. Prior to initiating a systematic literature review, sponsors should define the target population, device use scenarios, relevant clinical endpoints, and acceptable safety thresholds. A structured PICO framework (Population, Intervention, Comparator, Outcome) ensures that the literature search is aligned with specific safety and effectiveness questions.

Principle 2: Use a Systematic and Transparent Literature Search Strategy

FDA expects literature to be systematically identified, not selectively curated. Literature reviews used in submissions must be reproducible, comprehensive, and objectively documented. Further, the literature included must be systematically identified and critically evaluated in an unbiased fashion. Consistent with systematic literature review methodologies, the literature review protocol should be developed prospectively and include rationales for inclusion and exclusion of evidence. The methodological principles outlined in the Cochrane Handbook provide guidance on how to conduct a systematic literature review and reporting according to the PRISMA guidelines, which offer a means to recognize systematic reviews and meta-analyses that adhere to high standards of scientific rigor and transparency.

Principle 3: Apply Rigorous Study Selection and Critical Appraisal

Not all published studies are suitable for regulatory submissions and decision-making. While FDA emphasizes that high-quality literature should demonstrate sound study design, clearly defined endpoints, and consistent findings across studies describing use of the subject/like device, it is often possible to leverage valuable data from observational studies and case series. Some factors that strengthen acceptability include multiple studies from independent investigators, clear statistical methods and predefined endpoints, and use of objective, measurable clinical outcomes. Structured appraisal criteria (e.g., bias assessment, study quality scoring) should be applied to evaluate each study.

Principle 4: Demonstrate Direct Applicability to the Device and Intended Use

A common reason for regulatory rejection is lack of applicability. FDA expects the literature to reflect the same or highly similar device technology, comparable patient populations, and relevant clinical endpoints generated during clinical practice that is representative of the US. If differences exist, those differences should be explicitly identified and addressed through bridging arguments, supplementary data, or other supporting evidence demonstrating continued applicability.

Principle 5: Synthesize Evidence to Support Safety and Effectiveness

FDA evaluates the totality of evidence, not individual studies. Key considerations include consistency of findings across studies, heterogeneity in patient populations and endpoints, magnitude and durability of clinical benefit, and frequency and severity of adverse events. Under FDA’s benefit-risk framework, uncertainty is explicitly considered. A recommended approach is to present the evidence in structured formats, such as summary tables, narrative synthesis tied to the regulatory questions, and quantitative pooling when appropriate.

Principle 6: Address Gaps, Bias, and Uncertainty Transparently

Even strong datasets have limitations. FDA expects sponsors to identify gaps and potential biases, assess uncertainty explicitly, and explain why the conclusions remain valid to the subject device when used in the US. Use a structured risk-benefit justification to demonstrate that evidence remains sufficient, risks are understood and acceptable, and residual risk does not undermine safety.

Principle 7: Integrate Literature with the Totality of Evidence

Published literature rarely stands alone in regulatory submissions. FDA may expect integration with non-clinical testing, bench or simulation data, and labeling. The FDA guidance on real-world evidence emphasizes evaluating the relevance, reliability, and generalizability of the evidence. Building a narrative in the submission shows how all data sources complement each other; the narrative should provide consistent conclusions and strengthen overall confidence.

Conclusion

Executing an FDA-ready literature strategy requires more than a bibliographic search. Successful literature-based submissions consistently rely on experienced, unbiased medical writers and scientific communications specialists who contribute by:

• Designing methodologically sound literature strategies
• Ensuring alignment with FDA expectations and guidance
• Structuring evidence for regulatory clarity
• Translating complex findings into coherent benefit–risk narratives

When these principles are applied, literature becomes more than supporting information – it can become the foundation of an FDA decision related to safety and effectiveness. Published clinical literature can be a powerful tool for supporting, for example, expanded indications/labeling for an already available device. Given FDA’s expectations for systematic identification, transparent methodology, and critical appraisal, the contribution of specialized teams, such as MED Institute’s Scientific Communications team, is essential for developing systematic literature reviews that are scientifically rigorous, regulatory defensible, and clearly communicated. Our cross-functional team draws from our Regulatory and Clinical service areas and is well equipped to support methodical evidence gathering while upholding the highest standards of safety and effectiveness for patients. Contact us to have a conversation in support of your product!

855.463.1633 | askmed@medinstitute.com | medinstitute.com